Literature DB >> 32648294

COVID-19: Phylogenetic approaches may help in finding resources for natural cure.

Wajid Zaman1,2, Saddam Saqib1,2, Fazal Ullah2,3, Asma Ayaz4, Jianfei Ye1,5.   

Abstract

Entities:  

Year:  2020        PMID: 32648294      PMCID: PMC7405213          DOI: 10.1002/ptr.6787

Source DB:  PubMed          Journal:  Phytother Res        ISSN: 0951-418X            Impact factor:   6.388


× No keyword cloud information.
Coronavirus belongs to the family Coronaviridae, is one of the large family of viruses, which parasite on different animal species, including bats, camels, and cattle (Biscayart et al., 2020). A new strain named COVID‐19 by the World Health Organization (WHO) on February 11, 2020 shares the same clade within the subgenus sarbecovirus of the subfamily Orthocoronavirinae (Zhu et al., 2020). COVID‐19, which was formerly named 2019‐nCoV (Chen, Liu, & Guo, 2020; Zhou et al., 2020) causes respiratory, digestive, hepatic, and central nervous systems diseases in humans, animals, birds, and rodents. This virus infects humans through various means and spread between humans to humans, like MERS‐CoV, SARS‐CoV (Sousou, 2015), and now with this new virus named (SARS‐CoV‐2) (Albarello et al., 2020). Due to the epidemic nature and high rate of deaths, it is essential to develop prevention and therapeutic approaches for the control of this virus. A team of Chinese scientists at the National Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, China, has already started work on designing an effective drug against 2019‐nCoV (Khan, Ali, Siddique, & Nabi, 2020; Yuan, 2020). Another research group, Rolf Hilgenfeld (University of Lübeck, Germany), has been working on two compounds to test for their efficiency in contradiction of 2019‐nCoV (The Star Times, 2020). University of Queensland, GeoVax Labs Inc, and other world‐class research teams have also been joining in the research of vaccine development (Chinese Center for Disease Control and Prevention, 2020; Wang & Jin, 2020). Additionally, an investigation team in Shenzhen and Shanghai have already isolated the 2019‐nCoV and established the first applicant vaccine which will be available by next month for trials (Khan et al., 2020). Although in many cases there is a lack of good clinical evidence supporting the use of herbal extracts and preparations (Williamson, Liu, & Izzo, 2020), the mass media has stated that some individuals are seeking “alternative” medicines to avoid infection with COVID‐19 (National Center for Complementary and Integrative Health [NCCIH], 2020). Among them, Traditional Chinese Medicine (TCM) is on the top (Luo et al., 2020; Wang, Li, Yan, & Yao, 2020; Xu et al., 2020). TCMs have been used for thousands of years for the ailments of different diseases (Luo, Wang, Hesse‐Fong, Lin, & Yuan, 2019; Ryu, 2018). TCM consultants use several awareness and body practices (acupuncture, tai chi, Chinese herbal products) to report some health issues. The researcher reported that TCM specialists had been sent to Hubei for the treatment and research (The Economic Times, 2020). The treatment for the COVID‐19 in Wuhan hospital combines TCM and western medicines. The combination of western medicines and TCM had been given to more than half of confirmed cases in Hubei province. Eighteen people infected with COVID‐19 in Wuhan (Hubei province), were cured and discharged from the local hospital, after receiving combined treatment of TCM and Western medicine (China Daily, 2020a). The patients' ages ranged from 23 to 67‐year old, and one of them was observed in a severe condition, reported by Hubei Provincial Hospital of Integrated Chinese and Western Medicine. The patient was admitted to the hospital for 18 days, the longest among the 18 patients, the hospital reported. Head of the Beijing Hospital of TCM Liu Qingquan said: “Compared with the rapid development of Western medicine in recent years, research into TCM has declined. We need to put more importance on TCM and draw on the legacy of TCM treatment of acute diseases to help us fight infectious diseases today.” Another report said that the first group of 23 patients have recovered from COVID‐19 pneumonia and discharged on Wednesday morning from Jiangxia Makeshift Hospital, the first Medical institute, which completely accomplished by TCM doctors (China Daily, 2020b). At the start of the operation on 14 February, Makeshift Hospital had admitted 398 patients, with nobody degrading to critical condition, rendering to the hospital. “All these TCM methods largely improve patients' immune system and help in fighting the virus. We are confident that all patients will be cured in the next month,” Said Zhu Ying, vice‐president of the First Hospital of Hunan University, whose team has cured more than 14 patients till now. The official report said that as of 21st February that 3,200 competent TCM medical employees partaken in treating virus patients in Hubei province, and TCM has been used to treat 60,107 infected patients, or about 85.2% of the entire infected throughout the mainland, as of 17 February (China Daily, 2020b). As natural product research grows, such frameworks provide novel visions into how knowledge of traditional medicinal plants is working and might be used for the new COVID‐19. Progressively, though, there is encouragement for including traditional data of herbal medicine in the exploration of novel medicines for the treatment of viruses. The available knowledge on the traditional plants used are suggested suitable targets for examination bio screening in related clades (Saslis‐Lagoudakis et al., 2011). The results that traditional medicinal plants showed strong phylogenetic clustering specifies aiming close relatives of plants with known bioactivity or phylogenetic medicinal hotspots known as hot nodes is a good approach for focused screening (Rønsted et al., 2012; Yessoufou, Daru, & Muasya, 2015). Phylogenetic study plays an important role in the biological screening of clades of various plant species (Halse‐Gramkow, Ernst, Rønsted, Dunn, & Saslis‐Lagoudakis, 2016). The traditional knowledge is useful and can help in highlighting plant species in specific clades, to increase the number of relevant assays on these plant species which may similarly help in raising the success rates (Saslis‐Lagoudakis et al., 2012). There is a lot of work that has been done on the advancement of interdisciplinary relationships about the promotion of TCM phylogenetic knowledge. This is most significant as there is an extensive step of erosion of traditional knowledge on plants used globally, and such research might lead to well thoughtful gratitude for the biological and chemical foundations of traditional medicine. Currently, there are no drugs and vaccines to treat COVID‐19 approved by government agencies elsewhere. Same as Chinese scientists, it is recommended to use urgent precautions to cure infections caused by viruses all over the world. Using phylogenetic approaches may be helpful in finding herbal plants related to TCM plants in the world to find the best candidate for the treatment of COVID‐19.

CONFLICT OF INTEREST

We declare no conflict of interest for this study.
  17 in total

1.  Phylogenetic exploration of commonly used medicinal plants in South Africa.

Authors:  Kowiyou Yessoufou; Barnabas H Daru; Abraham Muthama Muasya
Journal:  Mol Ecol Resour       Date:  2014-08-12       Impact factor: 7.090

Review 2.  Trends in use, pharmacology, and clinical applications of emerging herbal nutraceuticals.

Authors:  Elizabeth M Williamson; Xinmin Liu; Angelo A Izzo
Journal:  Br J Pharmacol       Date:  2020-02-06       Impact factor: 8.739

3.  Can phylogeny predict chemical diversity and potential medicinal activity of plants? A case study of Amaryllidaceae.

Authors:  Nina Rønsted; Matthew R E Symonds; Trine Birkholm; Søren Brøgger Christensen; Alan W Meerow; Marianne Molander; Per Mølgaard; Gitte Petersen; Nina Rasmussen; Johannes van Staden; Gary I Stafford; Anna K Jäger
Journal:  BMC Evol Biol       Date:  2012-09-14       Impact factor: 3.260

4.  A pneumonia outbreak associated with a new coronavirus of probable bat origin.

Authors:  Peng Zhou; Xing-Lou Yang; Xian-Guang Wang; Ben Hu; Lei Zhang; Wei Zhang; Hao-Rui Si; Yan Zhu; Bei Li; Chao-Lin Huang; Hui-Dong Chen; Jing Chen; Yun Luo; Hua Guo; Ren-Di Jiang; Mei-Qin Liu; Ying Chen; Xu-Rui Shen; Xi Wang; Xiao-Shuang Zheng; Kai Zhao; Quan-Jiao Chen; Fei Deng; Lin-Lin Liu; Bing Yan; Fa-Xian Zhan; Yan-Yi Wang; Geng-Fu Xiao; Zheng-Li Shi
Journal:  Nature       Date:  2020-02-03       Impact factor: 69.504

5.  The next big threat to global health? 2019 novel coronavirus (2019-nCoV): What advice can we give to travellers? - Interim recommendations January 2020, from the Latin-American society for Travel Medicine (SLAMVI).

Authors:  Cristian Biscayart; Patricia Angeleri; Susana Lloveras; Tânia do Socorro Souza Chaves; Patricia Schlagenhauf; Alfonso J Rodríguez-Morales
Journal:  Travel Med Infect Dis       Date:  2020-01-30       Impact factor: 6.211

6.  A Novel Coronavirus from Patients with Pneumonia in China, 2019.

Authors:  Na Zhu; Dingyu Zhang; Wenling Wang; Xingwang Li; Bo Yang; Jingdong Song; Xiang Zhao; Baoying Huang; Weifeng Shi; Roujian Lu; Peihua Niu; Faxian Zhan; Xuejun Ma; Dayan Wang; Wenbo Xu; Guizhen Wu; George F Gao; Wenjie Tan
Journal:  N Engl J Med       Date:  2020-01-24       Impact factor: 91.245

7.  2019-novel Coronavirus severe adult respiratory distress syndrome in two cases in Italy: An uncommon radiological presentation.

Authors:  Fabrizio Albarello; Elisa Pianura; Federica Di Stefano; Massimo Cristofaro; Ada Petrone; Luisa Marchioni; Claudia Palazzolo; Vincenzo Schininà; Emanuele Nicastri; Nicola Petrosillo; Paolo Campioni; Petersen Eskild; Alimuddin Zumla; Giuseppe Ippolito
Journal:  Int J Infect Dis       Date:  2020-02-26       Impact factor: 3.623

Review 8.  Emerging coronaviruses: Genome structure, replication, and pathogenesis.

Authors:  Yu Chen; Qianyun Liu; Deyin Guo
Journal:  J Med Virol       Date:  2020-02-07       Impact factor: 2.327

9.  The progress of 2019 novel coronavirus event in China.

Authors:  Guan Wang; Xian Jin
Journal:  J Med Virol       Date:  2020-02-26       Impact factor: 2.327

Review 10.  Can Chinese Medicine Be Used for Prevention of Corona Virus Disease 2019 (COVID-19)? A Review of Historical Classics, Research Evidence and Current Prevention Programs.

Authors:  Hui Luo; Qiao-Ling Tang; Ya-Xi Shang; Shi-Bing Liang; Ming Yang; Nicola Robinson; Jian-Ping Liu
Journal:  Chin J Integr Med       Date:  2020-02-17       Impact factor: 1.978

View more
  10 in total

1.  Some natural hypomethylating agents in food, water and environment are against distribution and risks of COVID-19 pandemic: Results of a big-data research.

Authors:  Mohammad Reza Besharati; Mohammad Izadi; Alireza Talebpour
Journal:  Avicenna J Phytomed       Date:  2022 May-Jun

2.  Exploring Barriers to Effective Implementation of Public Health Measures for Prevention and Control of COVID-19 Pandemic in Gamo Zone of Southern Ethiopia: Using a Modified Tanahashi Model.

Authors:  Negussie Boti Sidamo; Sultan Hussen; Tamiru Shibiru; Meseret Girma; Mulugeta Shegaze; Abera Mersha; Teshale Fikadu; Zeleke Gebru; Eshetu Andarge; Mustefa Glagn; Selamawit Gebeyehu; Bilcha Oumer; Gebremaryam Temesgen
Journal:  Risk Manag Healthc Policy       Date:  2021-03-19

3.  Phytocompounds and COVID-19: Two years of knowledge.

Authors:  Ester Pagano
Journal:  Phytother Res       Date:  2022-02-16       Impact factor: 6.388

4.  Withanone from Withania somnifera Attenuates SARS-CoV-2 RBD and Host ACE2 Interactions to Rescue Spike Protein Induced Pathologies in Humanized Zebrafish Model.

Authors:  Acharya Balkrishna; Subarna Pokhrel; Hoshiyar Singh; Monali Joshi; Vallabh Prakash Mulay; Swati Haldar; Anurag Varshney
Journal:  Drug Des Devel Ther       Date:  2021-03-11       Impact factor: 4.162

5.  Calcio-Herbal Medicine Divya-Swasari-Vati Ameliorates SARS-CoV-2 Spike Protein-Induced Pathological Features and Inflammation in Humanized Zebrafish Model by Moderating IL-6 and TNF-α Cytokines.

Authors:  Acharya Balkrishna; Sudeep Verma; Siva Kumar Solleti; Lakshmipathi Khandrika; Anurag Varshney
Journal:  J Inflamm Res       Date:  2020-12-31

Review 6.  Update on treatment and preventive interventions against COVID-19: an overview of potential pharmacological agents and vaccines.

Authors:  Yinan Xiao; Hanyue Xu; Wen Guo; Yunuo Zhao; Yuling Luo; Ming Wang; Zhiyao He; Zhenyu Ding; Jiyan Liu; Lei Deng; Fushen Sha; Xuelei Ma
Journal:  Mol Biomed       Date:  2020-12-03

7.  COVID-19: General Strategies for Herbal Therapies.

Authors:  Samaneh Soleymani; Ayeh Naghizadeh; Mehrdad Karimi; Azadeh Zarei; Raefeh Mardi; Gholamreza Kordafshari; Niusha Esmaealzadeh; Arman Zargaran
Journal:  J Evid Based Integr Med       Date:  2022 Jan-Dec

8.  Exploring Readiness towards Effective Implementation of Safety and Health Measures for COVID-19 Prevention in Nakhon-Si-Thammarat Community-Based Tourism of Southern Thailand.

Authors:  Apirak Bumyut; Sasithorn Thanapop; Dusanee Suwankhong
Journal:  Int J Environ Res Public Health       Date:  2022-08-15       Impact factor: 4.614

9.  Influence of Disease Severity and Gender on HLA-C Methylation in COVID-19 Patients.

Authors:  Mohsen Sharif-Zak; Mojtaba Abbasi-Jorjandi; Gholamreza Asadikaram; Zohreh-Al-Sadat Ghoreshi; Mitra Rezazadeh-Jabalbarzi; Hamidreza Rashidinejad
Journal:  Iran J Sci Technol Trans A Sci       Date:  2022-07-27       Impact factor: 1.553

10.  Distribution of Therapeutic Efficacy of Ranunculales Plants Used by Ethnic Minorities on the Phylogenetic Tree of Chinese Species.

Authors:  Da-Cheng Hao; Yulu Zhang; Chun-Nian He; Pei-Gen Xiao
Journal:  Evid Based Complement Alternat Med       Date:  2022-01-12       Impact factor: 2.629

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.